In Vitro Diagnostic Fibrin Monomer Paracoagulation Test - Final Guidance for Industry and FDA Reviewers/Staff
Document issued on: April 27, 1999
U.S. Department Of Health And Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Hematology and Pathology Branch
Division of Clinical Laboratory Devices
Office of Device Evaluation
Comments and suggestions may be submitted at any time for Agency consideration to, Division of Clinical Laboratory Devices, Center for Devices and Radiological Health, HFZ-440, 9200 Corporate Boulevard, Rockville, MD 20850. Comments may not be acted upon by the Agency until the document is next revised or updated. For questions regarding the use or interpretation of this guidance contact Dr. Joseph Hackett at (301) 594-3084 or by electronic mail at JLH@cdrh.fda.gov.
Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number (2242) to identify the guidance you are requesting.
In Vitro Diagnostic Fibrin Monomer Paracoagulation Test;
Final Guidance for Industry and FDA Reviewers/Staff
NOTE: As stated in the final rule reclassifying the Fibrin Monomer Paracoagulation Test in vitro diagnostic devices from Class III to Class II, this guidance document is the special control for this device.
This draft guidance document describes a means by which Fibrin Monomer Paracoagulation Test in vitro diagnostic devices may comply with the requirement of special controls for class II devices. Designation of this guidance document as a special control means that manufacturers attempting to establish that their device is substantially equivalent to a predicate device should demonstrate that the proposed device complies with either the specific recommendations of this guidance or some alternative control that provides equivalent assurances of safety and effectiveness.
This guidance document represents the agency's current thinking on Fibrin Monomer Paracoagulation Tests. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both.
I. Device Description
Common Name(s): Fibrin Monomer Paracoagulation Test
Classification Panel: Hematology (81)
Product Codes: None
Regulation numbers: 21 CFR 864.7300
A fibrin monomer paracoagulation test is a device used to detect fibrin monomer in the diagnosis of disseminated intravascular coagulation (nonlocalized clotting within a blood vessel) or in the differential diagnosis between disseminated intravascular coagulation (DIC) and primary fibrinolysis (dissolution of the fibrin in a blood clot).
II. Indications for Use
Fibrin monomer tests are assays used to monitor the proteolytic cleavage of fibrinogen by thrombin and the resulting generation of soluble fibrin monomers. Fibrin monomer assays give direct evidence of thrombin activity on fibrinogen. It may aid in the diagnosis and/or exclusion of prethrombotic and thrombotic events such as pre-DIC, DIC or venous thrombosis. Additionally, soluble fibrin monomers can be used as aids for monitoring the response to DIC therapy.
Measurements obtained by this device are used in the diagnosis of disseminated intravascular coagulation. The intended patient population may be adult, pediatric, and neonatal, while the environment of use may be a hospital (e.g., respiratory care or laboratory department), urgent care situations (e.g., intensive care unit, surgery, emergency department), or bedside/near patient care situations.
III. Specific Performance Characteristics
A. Analytical Studies
The following performance characteristics should be included in the submission. Data should be provided that supports the use of the device in the intended population:
- within-run (assay, and
- between-run (assay), or
- mean(s), standard deviation (s), and coefficient(s) of variation at medical decision levels and over entire range of values
- total measurement error at selected decision points
- recovery or dilution
- minimum detection limit, or
- analytical sensitivity
- endogenous, e.g., bilirubin, hemoglobin, lipids, etc.
- exogenous, e.g., drugs, anticoagulants, etc.
- Stability Summary
- calibration interval
- quality control interval
- quality control materials
- calibration materials
- validation information
- certification information
- Expected Values
- population study, reference interval,
- medical decision point(s) and/or
- critical decision point(s)
- Cut-off established to differentiate normal and abnormal samples.
- describe method by which cut-off was established
- data showing calibration against recognized standard
- Analytical specificity
B. Clinical Studies
A method comparison study, comparing performance of the proposed device with that of the predicate device as well as an appropriate reference method should be conducted to demonstrate substantial equivalence. A sampling of patients from a population representing the proposed intended use should be included in the study.
- Method Comparison
- Continuous data
- slope and intercept can be analyzed by linear regression analysis
- correlation coefficient, include confidence interval where appropriate
- number and range of samples tested
- standard error of the estimate
- bias and bias plot
- graphical representation of the data
- Dichotomous data can be presented in a 2x2 table comparing both methods.
- estimates of sensitivity and specificity with confidence intervals should be included
IV. Labeling Considerations:
Refer to 21 CFR 809.10.
Instructions: Use this checklist for premarket notification for Fibrin Monomer Paracoagulation Test as a guide in preparing your submission.
Checklist Truthful and Accurate statement verbatim as per 21 CFR 807.87(j). 510(k) summary or statement per 21 CFR 807.92 or 21 CFR 807.93 respectively. Indications for use on a separate page. Labeling for in vitro diagnostic products (21 CFR 809.10 (b) Pre-Clinical Data: Interference Studies Linearity Studies Precision studies at medical decision levels Clinical Data (method comparison)
Methodologies to assist sponsors in establishing the specific performance characteristics addressed in part III of this document may be obtained using NCCLS documents
- Continuous data
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.